LIGAND PHARMACEUTICALS INC (LGNDZ)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 100M 200M 300M FY09: 38.9M FY10: 23.5M FY11: 30M FY12: 31.4M FY13: 49M FY14: 64.5M FY15: 71.9M FY16: 109M FY17: 141.1M FY18: 251.5M FY19: 120.3M FY20: 163.6M FY21: 241.5M FY22: 196.2M FY23: 131.3M FY24: 167.1M FY25: 268.1M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 90M 180M 270M FY16: 103.4M FY17: 135.7M FY18: 245.1M FY16 FY17 FY18

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-300M 0 300M 600M 900M FY09: -10M FY10: -29.3M FY11: -878K FY12: 193K FY13: 14.9M FY14: 19.6M FY15: 27.3M FY16: 43.9M FY17: 68.1M FY18: 163.7M FY19: 807.1M FY20: 37.5M FY21: 103.9M FY22: 3M FY23: 11.9M FY24: -22.6M FY25: 41M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-250M 0 250M 500M 750M FY09: -1.9M FY10: -10.4M FY11: 9.7M FY12: -527K FY13: 11.4M FY14: 12M FY15: 229.8M FY16: -1.6M FY17: 12.6M FY18: 143.3M FY19: 629.3M FY20: -3M FY21: 57.1M FY22: -33.4M FY23: 52.2M FY24: -4M FY25: 124.5M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 2.5M 5M 7.5M FY16: 5.6M FY17: 5.4M FY18: 6.3M FY16 FY17 FY18

Operating Cash Flow Annual

-70M 0 70M 140M 210M FY09: -33.8M FY10: -27.1M FY11: -1.2M FY12: 161K FY13: 20.7M FY14: 20.6M FY15: 41.7M FY16: 60.7M FY17: 88.6M FY18: 194.1M FY19: -29.3M FY20: 54.6M FY21: 78.8M FY22: 137.8M FY23: 49.6M FY24: 97M FY25: 49.4M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-70M 0 70M 140M 210M FY09: -34.3M FY10: -27.1M FY11: -1.2M FY12: -434K FY13: 20.3M FY14: 20.6M FY15: 41.6M FY16: 58.9M FY17: 86.4M FY18: 193.2M FY19: -31.9M FY20: 50.1M FY21: 70M FY22: 119.9M FY23: 46.1M FY24: 95.2M FY25: 48.9M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 9M 18M 27M FY09: 18.9M FY10: 19.6M FY11: 19.7M FY12: 19.9M FY13: 20.7M FY14: 21.4M FY15: 21.2M FY16: 20.8M FY17: 23.5M FY18: 24.1M FY19: 19.8M FY20: 16.8M FY21: 17.2M FY22: 16.9M FY23: 17.8M FY24: 18.3M FY25: 20.3M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 0.00 15.00 30.00 45.00 Q4 '11: 0.50 Q1 '12: 0.07 Q2 '12: -0.04 Q3 '12: 0.16 Q4 '13: 0.55 Q1 '14: 0.58 Q2 '14: 0.35 Q3 '14: 0.32 Q4 '14: 0.57 Q1 '15: 0.51 Q2 '15: 1.55 Q3 '15: 10.77 Q4 '15: 10.72 Q1 '16: 10.98 Q2 '16: 9.57 Q3 '16: 0.34 Q4 '16: 0.20 Q1 '17: 0.12 Q2 '17: 0.68 Q3 '17: 0.99 Q4 '17: -1.18 Q1 '18: 0.43 Q2 '18: 3.16 Q3 '18: 5.60 Q4 '18: 5.60 Q1 '19: 35.09 Q2 '19: 31.36 Q3 '19: 27.75 Q4 '19: 29.34 Q1 '20: -3.44 Q2 '20: -1.38 Q3 '20: -0.99 Q4 '20: -0.21 Q1 '21: 2.30 Q2 '21: 2.77 Q3 '21: 3.99 Q4 '22: -1.99 Q1 '23: 1.25 Q2 '23: 1.43 Q3 '23: 0.82 Q4 '23: 2.90 Q1 '24: 5.32 Q2 '24: 2.31 Q3 '24: 2.51 Q4 '24: -0.22 Q1 '25: -7.18 Q2 '25: -4.06 Q3 '25: 2.01 Q4 '25: 5.89 Q1 '26: 7.43 Q2 '26: 9.41 Q1 '12 Q4 '14 Q3 '16 Q2 '18 Q1 '20 Q4 '22 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.